Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erin W Meermeier

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
F1000Research|June 16, 2018
Early clearance versus control: what is the meaning of a negative tuberculin skin test or interferon-gamma release assay following exposure to <i>Mycobacterium tuberculosis</i>?Erin W Meermeier, David M Lewinsohn
The Journal of Clinical Investigation|February 14, 2023
Revisiting checkpoint inhibitors for myeloma: maintenance after stem cell transplantErin W Meermeier, P Leif Bergsagel
Annual Review of Cancer Biology|October 4, 2024
Next-Generation Therapies for Multiple MyelomaErin W Meermeier, P Leif Bergsagel, Marta Chesi
Immunology and Cell Biology|February 17, 2018
MAIT cells and microbial immunityErin W Meermeier, Melanie J Harriff, Elham Karamooz, et al.
Seminars in Respiratory and Critical Care Medicine|August 3, 2018
Diagnostic Challenge of Tuberculosis HeterogeneityElisa Nemes, Erin W Meermeier, Thomas J Scriba, et al.
Plos Pathogens|August 4, 2025
Two-pore channels in MR1-dependent presentation of Mycobacterium tuberculosis infectionElham Karamooz, Se-Jin Kim, Jessie C Peterson, et al.
Nature Communications|August 17, 2016
Human TRAV1-2-negative MR1-restricted T cells detect S. pyogenes and alternatives to MAIT riboflavin-based antigensErin W Meermeier, Bruno F Laugel, Andrew K Sewell, et al.
Blood|August 27, 2025
An immunostimulatory CELMoD combination overcomes resistance to T-cell engagers caused by a high multiple myeloma burdenErin W Meermeier, Kirsten Pfeffer, Caleb K Stein, et al.
Scientific Reports|September 23, 2020
Alternative splicing of MR1 regulates antigen presentation to MAIT cellsGitanjali A Narayanan, Abhinav Nellore, Jessica Tran, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 17, 2016
Engineering of Isogenic Cells Deficient for MR1 with a CRISPR/Cas9 Lentiviral System: Tools To Study Microbial Antigen Processing and Presentation to Human MR1-Restricted T CellsBruno Laugel, Angharad Lloyd, Erin W Meermeier, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
F1000Research|June 16, 2018
Early clearance versus control: what is the meaning of a negative tuberculin skin test or interferon-gamma release assay following exposure to <i>Mycobacterium tuberculosis</i>?Erin W Meermeier, David M Lewinsohn
The Journal of Clinical Investigation|February 14, 2023
Revisiting checkpoint inhibitors for myeloma: maintenance after stem cell transplantErin W Meermeier, P Leif Bergsagel
Annual Review of Cancer Biology|October 4, 2024
Next-Generation Therapies for Multiple MyelomaErin W Meermeier, P Leif Bergsagel, Marta Chesi
Immunology and Cell Biology|February 17, 2018
MAIT cells and microbial immunityErin W Meermeier, Melanie J Harriff, Elham Karamooz, et al.
Seminars in Respiratory and Critical Care Medicine|August 3, 2018
Diagnostic Challenge of Tuberculosis HeterogeneityElisa Nemes, Erin W Meermeier, Thomas J Scriba, et al.
Plos Pathogens|August 4, 2025
Two-pore channels in MR1-dependent presentation of Mycobacterium tuberculosis infectionElham Karamooz, Se-Jin Kim, Jessie C Peterson, et al.
Nature Communications|August 17, 2016
Human TRAV1-2-negative MR1-restricted T cells detect S. pyogenes and alternatives to MAIT riboflavin-based antigensErin W Meermeier, Bruno F Laugel, Andrew K Sewell, et al.
Blood|August 27, 2025
An immunostimulatory CELMoD combination overcomes resistance to T-cell engagers caused by a high multiple myeloma burdenErin W Meermeier, Kirsten Pfeffer, Caleb K Stein, et al.
Scientific Reports|September 23, 2020
Alternative splicing of MR1 regulates antigen presentation to MAIT cellsGitanjali A Narayanan, Abhinav Nellore, Jessica Tran, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 17, 2016
Engineering of Isogenic Cells Deficient for MR1 with a CRISPR/Cas9 Lentiviral System: Tools To Study Microbial Antigen Processing and Presentation to Human MR1-Restricted T CellsBruno Laugel, Angharad Lloyd, Erin W Meermeier, et al.
Pageof 3